Our Team in the News

BioPlan Associates' Ronald Rader

Ron Rader, Sr. Dir. Technical Research: named Editor-in-Chief of Biopharmaceuticals a new peer-reviewed journal from Landes Bioscience. Biopharmaceuticals is the first and only peer-reviewed journal about biopharmaceuticals. Biopharmaceuticals seeks submission of articles concerning biopharmaceuticals and the industry. Please contact the Editor-in-Chief if interested in submitting an article.

BioPlan Associates' Faiz Kermani PhD

Dr Faiz Kermani, Advisory Board: Has helped establish the "Global Health Education Foundation" (GHEF), a not-for-profit healthcare charity to improve educational resources and training for healthcare professionals in developing countries.
At least 1.3 billion people worldwide lack access to the most basic healthcare. The new non-profit foundation, Global Health Education Foundation, aims to tackle such issues. As President of GHEF, Dr Kermani is supporting the R&D focus of the charity to reduce health disparities among developing countries. In particular, the lack of appropriate educational resources and training opportunities for healthcare professionals. http://www.globalhef.org

BioPlan Associates' Managing Director Eric Langer

Eric Langer, Managing Partner: On Advisory Board of “BioProcess Asia Pacific Conference” July 2010 Singapore.
The Biopharmaceutical market in Asia pacific is growing at a rate among the highest in the globe. This is creating a strong need for production of biopharmaceuticals at higher qualities and volumes. Bioprocess AsiaPacific brings together global leaders within biopharmaceutical industry to explore dynamic strategies, benchmark technologies and analyze sustaining the growth of the industry. http://fleminggulf.com/conference/life-science/BioProcessAsiaPacific.


New Technology & Product Evaluation Program

Global Biotechnology Innovation and Evaluation Services Overview

BioPlan Associates can help streamline your new product introductions. Click below to see how we can help get your technology into the hands of end-users, who can evaluate your product more quickly.

  • Time to Market reduced by 50%
  • Site Recruiting costs reduced by 25-30%
  • Receive end-user data, publishable, potentially attributable
  • Save on sample management and costs
Cost Optimizing
  • Marketing staff can focus on critical tasks, not site management
  • Pre-recruited sites provide data for marketing
  • Lowers sample management costs and protocol processes
Testing Optimization
  • Assured cross-lab and facilty data comparability
  • Testing never gets de-railed
  • Avoid inappropriate testing sites, or delayed results
  • Performance Testing provides in-house alternatives
Sales Rep Optimizing
  • Sales reps maintain positive relationships with test sites
  • Sales reps not de-focused doing project management
  • Sales staff can continue 'selling' rather than site recruiting
  • No harassing of test site to perform on schedule

› Benefits to Technology Innovators

  • Unique access to global commercial Process Development—425 biopharma evaluators and field testing staff, pre-recruited (10-year relations with panel of global major competent biomanufacturing facilities capable of providing real-world evaluations of new products and technologies (Biotechnology Industry Council™)
  • High-value, VP, director of commercial PD evaluations
  • Accelerate innovators’ new product evaluations; get new products into the right hands
  • Management of new product field testing & sample placement
  • Coordinated, multi-site testing, with integrated, compiled data
  • Managed evaluation programs between evaluators & vendors
  • Written, comparative analysis provided—test protocols, observe user interactions with your products through User-driven Innovation analysis; Standardized post-test reporting
  • Pre-screened technology evaluators to ensure technical qualifications
  • Peer-to-peer input regarding new technology
  • More data, from multiple commercial sites, much more quickly
  • Reduced time, costs, risks compared with in-house evaluations of new technology platforms
  • Speed beta testing and reduce time-to-market
  • Eliminate innovators’ internal staff and sales reps’ recruiting external facilities
  • Receive direct, unbiased, blinded feedback, from CRO Independent, unbiased reporting
  • Direct input for technology design, marketing strategy, pricing, positioning
  • Publishable, attributable data support is available
  • Dedicated project managers to assure IP confidentiality
  • Access testing facilities to support early-stage evaluation

› Benefits to Evaluators and End-users

  • Match your areas of interest in new bioprocessing, tools and technology with innovators who’ve developed new devices
  • Identify new technologies sooner by efficiently finding innovators who are unable to find you
  • Simplify your technology scouting by funneling global vendors’ new technologies right to you first
  • Reduce your contact time with sales rep/vendor (unless you want it!)
  • Easily say ‘no—I’m not interested’ to vendors
  • Ensure protocols are pre-tested and externally refined to simplify evaluations
  • Receive pre-testing basic data and results, from external, independent lab – helps you decide if it’s a relevant or not
  • Receive Design of Experiment support so you don’t have reinvent testing for each new process and each new technology